SUBSCRIBE
SUBSCRIBE
News   Policy

U.S. Judge Denies Sanofi-Aventis (France)'s Request to Get Lovenox Generic Rival Made by Novartis AG Blocked; Sanofi to Continue Fight

August 26, 2010 | 
1 min read
LONDON, Aug 26 (Reuters) - French drugmaker Sanofi-Aventis (SASY.PA) said it would continue a legal battle in the United States against a generic version of its blood clot preventer Lovenox, despite a court rebuff.
Legal
Novartis Sanofi
MORE ON THIS TOPIC
Approved and confirmed document file with check mark icon flat cartoon, concept of agreement or contract symbol with checkmark, accepted or certified license paper form pictogram isolated image
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Plan to buying new house or renovation, mortgage loan or housing expense, property maintenance or real estate insurance concept, smart businessman put jigsaw to complete or finishing house puzzle.
FDA
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
June 25, 2026
 · 
3 min read
 · 
Jef Akst
Isometric arrow overcoming above wall on turquoise blue background. Challenge, success, development and solution concept. Flat design. Vector illustration, no transparency, no gradients
Duchenne muscular dystrophy
REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy
June 24, 2026
 · 
2 min read
 · 
Gabrielle Masson
From left to right: Julie Tierney, former deputy director of the FDA’s Center for Biologics Evaluation and Research (CBER); Ian Simon, former lead of HHS’ Office of Long Covid; Demetre Daskalakis, former director of the CDC’s National Center for Immunization and Respiratory Diseases; Jennifer Eileen Towne, chief scientific officer at Vir Biotechnology; Jared Bauer, CEO and cofounder of Seek Labs
Policy
BIO 2026: US public health as we know it is gone. Can we rebuild a better system?
June 23, 2026
 · 
4 min read
 · 
Jef Akst